Mechanism of Action: Stem Cell Factor (KIT) Receptor Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: Stem Cell Factor (KIT) Receptor Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,023,325 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,059,410 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 12,213,968 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,344,536 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,844,788 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,529,336 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | 11,918,564 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
